Axess Vision Technology who develops single use instruments for endoscopy, limiting contamination risk, has closed a €3.5 Million second round of financing.
Investment was lead by several medical device investors including former investors CapDecisif Management and OTC Asset Management and new comers Sofimac Partners and Viveris Management.
Axess vision Technology develops sterile, single use endoscopes.
It’s first product called the « Broncoflex su® » is the first video bronchoscope of its kind to have obtained CE mark.
This novel device has similar functionalities found in reusable endoscopes and brings 24/7 product availability, while minimizing contamination risks.
Each patient benefits from a new device at all times, delivered sterile, ready to use. For the hospitals and healthcare in general, the Broncoflex su® implies a limited global examination cost.
Over 10 million bronchoscopies are performed each year worldwide, representing a €2.5 billion market.
The new financing round will allow commercial expansion and a broadening of the product range. The Company’s objective is to rapidly extend the product range to other endoscopy applications including but not limited to urology, gynecology, ENT and gastroenterology. '